2026-06-01T02:44:58Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/339672026-02-03T11:03:39Zcom_10630_2254col_10630_37953

Oliver-Martos, Begoña Mayorga Mayorga, Cristobalina Leyva-Fernández, Laura León, Antonio Luque, Gloria C Lopez, Juan Tamayo, Jose A Pinto-Medel, Maria Jesús De Ramón, Enrique Blanco, Eva Alonso, Ana Fernández Fernández, Óscar 2024-09-30T08:58:01Z 2024-09-30T08:58:01Z 2006 Oliver B, Mayorga C, Fernández V, Leyva L, León A, Luque G, López JC, Tamayo JA, Pinto-Medel MJ, de Ramon E, Blanco E, Alonso A, Fernández O. Interferon receptor expression in multiple sclerosis patients. J Neuroimmunol. 2007 Feb;183(1-2):225-31. doi: 10.1016/j.jneuroim.2006.11.010. Epub 2006 Dec 26. PMID: 17188754. https://hdl.handle.net/10630/33967 0.1016/j.jneuroim.2006.11.010 To determine the gene expression of IFNAR1, IFNAR2 and MxA protein and the association with IFNbeta treatment response in MS patients. MS patients treated with IFNbeta had a significant decrease in IFNAR1 and IFNAR2 expression, and a significant increase in MxA compared to non-treated patients and healthy controls. Also, those patients who had a good response to treatment had a significant decrease in IFNAR1 and IFNAR2 expression compared to non-responders, non-treated patients and healthy controls. IFNbeta influences the expression of its receptors, and is greater in patients who respond to IFNbeta treatment. This down-regulation could be indicative of the response to IFNbeta. eng open access Esclerosis múltiple Interferon receptor expression in multiple sclerosis patients journal article